Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment DOI Open Access
Victoria Serhiyenko, A.A. Serhiyenko

World Journal of Diabetes, Journal Year: 2018, Volume and Issue: 9(1), P. 1 - 24

Published: Jan. 10, 2018

Cardiac autonomic neuropathy (CAN) is a serious com-plication of diabetes mellitus (DM) that strongly associated with approximately five-fold increased risk cardiovascular mortality.CAN manifests in spectrum things, ranging from resting tachycardia and fixed heart rate (HR) to development "silent" myocardial infarction.Clinical correlates or markers for CAN are age, DM duration, glycemic control, hypertension, dyslipidemia (DLP), other microvascular complications.Established factors poor control type 1 combination DLP, obesity, unsatisfactory 2 DM.Symptomatic manifestations include sinus tachycardia, exercise intolerance, orthostatic hypotension (OH), abnormal blood pressure (BP) regulation, dizziness, presyncope syncope, intraoperative instability, asymptomatic ischemia infarction.Methods assessment clinical practice symptoms signs, reflex tests based on HR BP, short-term electrocardiography (ECG), QT interval prolongation, variability (24 h, classic 24 h Holter ECG), ambulatory BP monitoring, turbulence, baroreflex sensitivity, muscle sympathetic nerve activity, catecholamine tests, imaging.Although it common complication, the significance has not been fully appreciated there no unified treatment algorithms today.Treatment early diagnosis, life style changes, optimization management factors.Pathogenetic includes: Balanced diet physical activity; control; DLP; antioxidants, first all α-lipoic acid (ALA), aldose reductase inhibitors, acetyl-L-carnitine; vitamins, fat-soluble vitamin B1; correction vascular endothelial dysfunction; prevention thrombosis; severe cases-treatment OH.The promising methods prescription prostacyclin analogues, thromboxane A2 blockers drugs contribute into strengthening and/or normalization Na + , K -ATPase (phosphodiesterase inhibitor), ALA, dihomo-γ-linolenic (DGLA), ω-3 polyunsaturated fatty acids (ω-3 PUFAs), simultaneous PUFAs DGLA, but future investigations

Language: Английский

The Evolving Future of PCSK9 Inhibitors DOI Creative Commons
Robert S. Rosenson, Robert A. Hegele, Sergio Fazio

et al.

Journal of the American College of Cardiology, Journal Year: 2018, Volume and Issue: 72(3), P. 314 - 329

Published: July 1, 2018

Language: Английский

Citations

215

American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update DOI Open Access
Susan L. Samson, Priyathama Vellanki, Lawrence Blonde

et al.

Endocrine Practice, Journal Year: 2023, Volume and Issue: 29(5), P. 305 - 340

Published: May 1, 2023

Language: Английский

Citations

213

ISPAD Clinical Practice Consensus Guidelines 2018: Nutritional management in children and adolescents with diabetes DOI Open Access
Carmel E. Smart, Francesca Annan,

Laurie Higgins

et al.

Pediatric Diabetes, Journal Year: 2018, Volume and Issue: 19, P. 136 - 154

Published: July 30, 2018

Language: Английский

Citations

211

Lipid management in patients with chronic kidney disease DOI
Charles J. Ferro, Patrick B. Mark, Mehmet Kanbay

et al.

Nature Reviews Nephrology, Journal Year: 2018, Volume and Issue: 14(12), P. 727 - 749

Published: Oct. 25, 2018

Language: Английский

Citations

208

Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment DOI Open Access
Victoria Serhiyenko, A.A. Serhiyenko

World Journal of Diabetes, Journal Year: 2018, Volume and Issue: 9(1), P. 1 - 24

Published: Jan. 10, 2018

Cardiac autonomic neuropathy (CAN) is a serious com-plication of diabetes mellitus (DM) that strongly associated with approximately five-fold increased risk cardiovascular mortality.CAN manifests in spectrum things, ranging from resting tachycardia and fixed heart rate (HR) to development "silent" myocardial infarction.Clinical correlates or markers for CAN are age, DM duration, glycemic control, hypertension, dyslipidemia (DLP), other microvascular complications.Established factors poor control type 1 combination DLP, obesity, unsatisfactory 2 DM.Symptomatic manifestations include sinus tachycardia, exercise intolerance, orthostatic hypotension (OH), abnormal blood pressure (BP) regulation, dizziness, presyncope syncope, intraoperative instability, asymptomatic ischemia infarction.Methods assessment clinical practice symptoms signs, reflex tests based on HR BP, short-term electrocardiography (ECG), QT interval prolongation, variability (24 h, classic 24 h Holter ECG), ambulatory BP monitoring, turbulence, baroreflex sensitivity, muscle sympathetic nerve activity, catecholamine tests, imaging.Although it common complication, the significance has not been fully appreciated there no unified treatment algorithms today.Treatment early diagnosis, life style changes, optimization management factors.Pathogenetic includes: Balanced diet physical activity; control; DLP; antioxidants, first all α-lipoic acid (ALA), aldose reductase inhibitors, acetyl-L-carnitine; vitamins, fat-soluble vitamin B1; correction vascular endothelial dysfunction; prevention thrombosis; severe cases-treatment OH.The promising methods prescription prostacyclin analogues, thromboxane A2 blockers drugs contribute into strengthening and/or normalization Na + , K -ATPase (phosphodiesterase inhibitor), ALA, dihomo-γ-linolenic (DGLA), ω-3 polyunsaturated fatty acids (ω-3 PUFAs), simultaneous PUFAs DGLA, but future investigations

Language: Английский

Citations

206